Log in

NASDAQ:MLNDMillendo Therapeutics Stock Price, Forecast & News

$1.72
+0.01 (+0.58 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.66
Now: $1.72
$1.73
50-Day Range
$1.63
MA: $2.13
$3.28
52-Week Range
$1.26
Now: $1.72
$12.81
Volume630,936 shs
Average Volume952,131 shs
Market Capitalization$32.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; and nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia. Millendo Therapeutics, Inc. is headquartered in Ann Arbor, Michigan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MLND
CUSIPN/A
CIKN/A
Phone734-845-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$290,000.00
Book Value$3.28 per share

Profitability

Net Income$-44,570,000.00

Miscellaneous

Employees37
Market Cap$32.68 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive MLND News and Ratings via Email

Sign-up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter.

Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions

How has Millendo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Millendo Therapeutics' stock was trading at $6.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MLND stock has decreased by 73.9% and is now trading at $1.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Millendo Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Millendo Therapeutics.

When is Millendo Therapeutics' next earnings date?

Millendo Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Millendo Therapeutics.

How were Millendo Therapeutics' earnings last quarter?

Millendo Therapeutics Inc (NASDAQ:MLND) issued its quarterly earnings results on Friday, May, 8th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.02. View Millendo Therapeutics' earnings history.

What price target have analysts set for MLND?

7 Wall Street analysts have issued 1-year price objectives for Millendo Therapeutics' shares. Their forecasts range from $2.00 to $26.00. On average, they anticipate Millendo Therapeutics' share price to reach $10.14 in the next twelve months. This suggests a possible upside of 489.7% from the stock's current price. View analysts' price targets for Millendo Therapeutics.

Has Millendo Therapeutics been receiving favorable news coverage?

Headlines about MLND stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Millendo Therapeutics earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Millendo Therapeutics.

Are investors shorting Millendo Therapeutics?

Millendo Therapeutics saw a increase in short interest in June. As of June 15th, there was short interest totaling 561,100 shares, an increase of 5.9% from the May 31st total of 529,800 shares. Based on an average trading volume of 1,100,000 shares, the days-to-cover ratio is presently 0.5 days. Currently, 4.2% of the shares of the company are sold short. View Millendo Therapeutics' Current Options Chain.

Who are some of Millendo Therapeutics' key competitors?

What other stocks do shareholders of Millendo Therapeutics own?

Who are Millendo Therapeutics' key executives?

Millendo Therapeutics' management team includes the following people:
  • Dr. Julia C. Owens Ph.D., CEO, Pres & Director (Age 47, Pay $702.8k)
  • Mr. Louis J. Arcudi III, M.B.A., MBA, Chief Financial Officer (Age 59, Pay $495.79k)
  • Dr. Ryan Zeidan Ph.D., Chief Devel. Officer (Age 40, Pay $511.69k)
  • Dr. Gary Hammer M.D., Ph.D., Co-Founder and Chairman of Scientific Advisory Board
  • Ms. Tamara Lynn Joseph, Gen. Counsel & Corp. Sec. (Age 57)

What is Millendo Therapeutics' stock symbol?

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

How do I buy shares of Millendo Therapeutics?

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Millendo Therapeutics' stock price today?

One share of MLND stock can currently be purchased for approximately $1.72.

How big of a company is Millendo Therapeutics?

Millendo Therapeutics has a market capitalization of $32.68 million and generates $290,000.00 in revenue each year. The company earns $-44,570,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Millendo Therapeutics employs 37 workers across the globe.

What is Millendo Therapeutics' official website?

The official website for Millendo Therapeutics is www.millendo.com.

How can I contact Millendo Therapeutics?

Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.